Lansoprazole Orally Disintegrating 15mg
Lansoprazole is a benzimidazole proton pump inhibitor that irreversibly inhibits H⁺/K⁺-ATPase on the gastric parietal cell through the same prodrug activation mechanism shared by all PPIs — conversion to a sulphenamide at low pH in the secretory canaliculus, forming a covalent bond with the proton pump enzyme. Among PPIs, lansoprazole has a unique pharmacological profile: it is particularly effective in reducing nocturnal acid breakthrough (acid secretion during nighttime that escapes daytime PPI suppression) and achieves higher intragastric pH elevation in some patient populations compared to omeprazole.
The Orally Disintegrating Tablet (ODT) formulation of lansoprazole dissolves on the tongue without water — the lansoprazole granules within the ODT are enteric-coated to protect them from oral and gastric acid degradation. The ODT format allows the granules to be swallowed after tongue disintegration, where they dissolve in the small intestinal alkaline environment for absorption. This makes lansoprazole ODT the only PPI that can be reliably administered to: patients with nasogastric tubes (dissolve in water, administer via tube), paediatric patients who cannot swallow capsules, elderly patients with dysphagia, and patients with swallowing disorders.
At 15mg, LAPSON 15 provides the lower maintenance dose used for GORD maintenance therapy and paediatric dosing — distinct from the 30mg dose used for acute healing.
LAPSON 15 is indicated for acid-related conditions in adults and paediatric patients where the oral disintegrating format provides a clinical advantage over conventional PPI capsules.
Paediatric GORD (Primary Indication): GORD in infants and children — lansoprazole ODT is specifically approved for paediatric GORD from 1 year of age. The 15mg dose covers children 10–30 kg; for children below 10 kg, 7.5mg (half tablet dissolved in water) may be used. The ODT format eliminates the challenge of administering PPI capsules to children.
GORD Maintenance (Adults): 15mg once daily for long-term GORD symptom control after initial 30mg healing course — a standard step-down maintenance regimen.
Non-Erosive Reflux Disease (NERD): Symptomatic GORD without oesophageal erosions — 15mg effectively controls symptoms with a favourable benefit-risk profile for long-term use.
Peptic Ulcer Prevention: Low-dose PPI for NSAID-associated ulcer prophylaxis in at-risk patients requiring long-term NSAID therapy.
Nasogastric Tube Administration: The ODT granules can be dissolved in water and administered through NG or PEG tubes — the only practical PPI option for enterally-fed patients requiring acid suppression.
H. pylori Eradication: As the PPI component of triple therapy in patients where capsule swallowing is problematic.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
Lansoprazole ODT fills a genuine clinical gap in PPI prescribing — it is the only PPI specifically approved for paediatric use from age 1, and the only PPI format practically deliverable through nasogastric or PEG tubes for enterally-fed patients. These two distinct patient populations — paediatric GORD patients and tube-fed ICU/post-surgical patients — have no practical alternative to lansoprazole ODT when PPI therapy is required.
For paediatric gastroenterologists and neonatologists managing infant GORD — one of the most common referral indications in paediatric practice — LAPSON 15 provides a safe, appropriately dosed, and practically administrable PPI option. The combination of paediatric indication, ODT format, and Alu-Alu packaging positions it as a premium niche product within the large GI PPI market.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.